Overview
|
China Pharma IP Summit is a serial event dedicated to pharmaceutical IP protection, and so far we have hold 2 sessions in the year of 2016 and 2017. Government agencies, pharmaceutical/biotech companies, law firms/ IP agencies and other IP solution providers have been invited to attend and we discussed lots of hot issues. Meanwhile, the event has been a good networking platform for industry experts both from local China and abroad.
2017 is a year of great significance in China pharmaceutical industry. On May 2017, China Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued, clearly putting forward the establishing patent linkage system, launching pilot program on drug patent extension, completing data protection and implementing list of marketed drugs. At the moment, China is conducting legislation for patent linkage and patent extension, which draws lots of attention.
In terms of intellectual property judicial, on Feb 2018, General Office of the CPC and General Office of the State Council issued Strengthening the Intellectual Property Judicial Reform and Innovation, which is the first guiding document regarding to intellectual property judicial. Pharmaceutical is heavily relied on IP protection, and we predict the guiding document will have influence on pharmaceutical IP litigation in China.
Based on the background, we are glad to inform that 3rd China Pharma IP Summit 2018 will be hold on 24th -26th October in Beijing, providing a platform to discuss updated policies and hot issues.
Through the event, you will have chance to:
1. Follow the latest development of patent linkage and patent term extension reform in China
2. Understand the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.
3. Learn IP management experience from pharmaceutical company
4. Meet you clients/partners fact to face and interact with industry peers
The participants are mainly from pharma/biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!
Thanks again for your attention and looking forward to your participation!
|
|
Agenda:
|
Day1：24, Oct. 2018
|
|
|
|
Day1 Morning: Policies Updated in China
|
|
|
|
0730
|
Registration
|
|
|
|
0840
|
Opening Remarks
Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association
|
|
|
|
0900
|
Pharmaceutical IP Index and Evaluation of Pre-Revenue Pharmaceutical Innovators Going Public in Hong Kong
Pharmaceutical companies developing new drugs in clinical trials can now file IPO in Hong Kong without any revenue if they have strong long term patent rights. Tony Chen (Jones Day) and Matthew Chervenak (General Biologic) will introduce a Pharmaceutical IP Index to measure true economic exclusivity of innovative drugs by taking into account patent term, patent strength, regulatory data protection and other factors. They will demonstrate how π Value will help the market assess the long term IP value of innovative pharmaceutical companies in China and explain the potential impact of pharmaceutical IP reform in China on innovation.
Tony Chen, Partner, Jones Day
Matthew Chervenak, Founder and CEO, General Biologic (GBI)
|
|
|
|
0930
|
Panel Discussion: Pharmaceutical Innovation and IP Protection in China
China is exploring to establish patent linkage and patent term extension system. The industry is waiting for more detailed implementation rules. We will invite experts to share the updates and developments.
Moderator:
Yongshun Cheng, Director, Beijing Intellectual Property Institute
Panelists:
Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association
Tony Chen, Partner, Jones Day
Taoxi Lin, IP Director, HEC Group
Elaine Li, Partner, ADVANCE CHINA IP LAW OFFICE
|
|
|
1040
|
Coffee Break
|
|
|
|
1110
|
Projecting Characteristics and Trends of Pharma Patent Invalidation in China under the New Patent Linkage System
Juhua Luo, Deputy Director of Chemical Patent Department, CCPIT Patent and Trademark Law Office
|
|
|
|
1150
|
The Patent Linkage for Pharmaceuticals -A Worldwide Perspective
Yehudah Livneh, Strategic IP Consultant;
Former General Patent Counsel and VP Corporate IP and Legislative Affairs, Teva Pharmaceuticals
|
|
|
|
1240
|
Lunch Buffet
|
|
|
|
Day 1 Afternoon: Focus on US
|
|
|
|
1400
|
Chair Speech
Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP
|
|
|
|
1405
|
Strategies to Improve Certainty and Reduce Costs in Paragraph IV Litigation
Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP
|
|
|
|
1440
|
Business Development of Pharma Companies in the Era of Big Data: Leveraging Patent Information in Strategic Partnership Scouting and Drug Development
Li Miao, IP Consultant, LexisNexis
|
|
|
|
1515
|
Coffee Break
|
|
|
|
1550
|
Navigating the IP/FDA Exclusivity Waters – Recent Developments Affecting The Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US
Christopher Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP
|
|
|
|
1625
|
Navigating the Safe Harbor Provision of the Hatch-Waxman Act
Alyson Wooten, Counsel, Kilpatrick Townsend & Stockton LLP
|
|
|
1700
|
Panel Discussion:Strengths and Risks in the Use of Patents to Protect Market Exclusivity in the US
Moderator:
Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP
Panelists:
Janet Xiao, Partner, Morrison & Foerster LLP
Cynthia Lan Martin, Senior Patent Attorney, AstraZeneca
Steven H. Sklar, Member, Leydig, Voit & Mayer
Yieyie Yang, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
|
|
|
|
1800
|
Cocktail (Sponsored by Womble Bond Dickinson (US) LLP
|
|
Day2: 25, Oct. 2018
|
|
|
|
Day2 Morning: Focus on China
|
|
0830
|
Chairman Opening Remark
Chairman: Li Wu, Senior Consultant, AnJie Law Firm
|
|
|
|
0840
|
Pharmaceutical High Value Patent Cultivation
Qiujuan Ma, Director for Pharmaceutical, Patent Examination Cooperation Center of SIPO
|
|
|
|
0920
|
Pharmaceutical Patent Trial in China
Chi Su, Director of IP Case Guidance Research (Beijing) Base of the Supreme People’s Court and President of Beijing IP Law Association; First President, Beijing Intellectual Property Court (Retired in Dec. 2017)
|
|
|
|
1000
|
Coffee Break
|
|
1030
|
Analyzing and Discussing Pharmaceutical Patent Infringement Litigation Case
HENG DU LAW FIRM
|
|
|
|
1110
|
Panel Discussion: Regulatory Data Protection in China
Moderator:
Chen Yang, Senior Counsel, Sidley Austin LLP
Panelists：
Xu Yang, Patent Attorney, BeiGene, Ltd.
Kent Yang, Head Patents China, Novartis Pharmaceuticals (China)
Yue Yang, Director, International Center for Food and Drug Policy and Law,
Shenyang Pharmaceutical University
|
|
|
|
1145
|
Panel Discussion: Hot Cases of Pharmaceutical Patent Invalidation in China and Implication
Moderator:
Li Wu, Senior Consultant, AnJie Law Firm
Panelists：
Xiaolan Ren, Director of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA (National Intellectual Property Administration, PRC)
Feng Xu, IP Director for China and Asia, AstraZeneca
Nick Liu, Partner, AnJie Law Firm (Former Senior Judge at Intellectual Property Division of Beijing Higher People’s Court)
|
|
|
|
1235
|
Lunch
|
|
|
|
Day2 Afternoon: Focus on EU
|
|
|
|
1400
|
Chair Speech
Andreas Oser, Partner, Prüfer & Partner
|
|
|
|
1405
|
The Latest Developments at EPO (including pertinent case law)
Klaus-Peter Döpfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO
|
|
1440
|
The Supplementary Protection Certificate in Europe and Potential Modification (including introduction of a manufacturing waiver)
Andreas Oser, Partner, Prüfer & Partner
|
|
1515
|
Coffee Break
|
|
1620
|
Is your invention plausible? The rising
importance of the “plausibility” hurdle in life science and pharmaceutical patents”
Hsu Min Chung, Partner, HGF Limited
|
|
|
|
1625
|
Secondary Patents - Current Developments And Challenges in Europe
Ute Kilger, Partner, Boehmert & Boehmert
Markus Engelhard, Partner, Boehmert & Boehmert
|
|
|
|
1700
|
Panel Discussion: Patent Protection and Enforcement of First, Second or Further Medical Uses of Known Compounds/Pharmaceutical Products in Europe
Moderator:
Andreas Oser, Partner, Prüfer & Partner
Panelists:
Hsu Min Chung, Partner, HGF Limited
Klaus-Peter Döpfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO
Ute Kilger, Partner, Boehmert & Boehmert
Markus Engelhard, Partner, Boehmert & Boehmert
|
|
Day3: 26, Oct. 2018
|
|
|
|
Day3 Morning: Other Region
|
|
|
|
0830
|
Chairman Opening Remark:
Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited
|
|
|
|
0840
|
Pharmaceutical Patent Protection and Patent Term Extension Regime in Japan
Koichiro Morihira, Head of Intellectual Property, Astellas Pharma Inc.
|
|
|
|
0920
|
Optimizing Overseas Pharma M&A Decisions– Big Data Supported IP Due Diligence
Chieh-Mei Wang, Vice President, ScienbiziP Consulting (Shen Zhen) Co., Ltd.
|
|
|
|
1000
|
Coffee Break
|
|
|
|
1035
|
The Generic Pharmaceutical in India and Patent Compulsory Licensing System
Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited
|
|
|
|
1110
|
US Updates and Effect on Pharmaceutical Companies
Todd Volyn, Associate Patent Counsel, Johnson & Johnson
|
|
|
|
1145
|
Conference Closing Remark
|
|
|
|
|
|
Organizing Committee
Endorser
Sponsor
|
